Sugarloaf Wealth Management LLC Has $1.03 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Sugarloaf Wealth Management LLC lifted its position in Johnson & Johnson (NYSE:JNJFree Report) by 6.4% during the 4th quarter, Holdings Channel reports. The firm owned 6,576 shares of the company’s stock after buying an additional 397 shares during the quarter. Sugarloaf Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,031,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. RPG Investment Advisory LLC increased its stake in shares of Johnson & Johnson by 1.2% during the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock valued at $807,000 after buying an additional 60 shares during the period. Texas Capital Bancshares Inc. TX increased its stake in shares of Johnson & Johnson by 1.1% during the second quarter. Texas Capital Bancshares Inc. TX now owns 5,744 shares of the company’s stock valued at $951,000 after buying an additional 61 shares during the period. FIDELIS iM LLC increased its stake in shares of Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after buying an additional 64 shares during the period. TFG Advisers LLC increased its stake in shares of Johnson & Johnson by 0.4% during the third quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock valued at $2,855,000 after buying an additional 67 shares during the period. Finally, Kellett Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 3.8% during the third quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock valued at $293,000 after buying an additional 68 shares during the period. Institutional investors own 68.40% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, February 20th. Raymond James lifted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $158.18 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The company has a market capitalization of $381.02 billion, a P/E ratio of 11.45, a P/E/G ratio of 2.71 and a beta of 0.53. The firm’s 50 day simple moving average is $159.58 and its two-hundred day simple moving average is $156.91.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the previous year, the firm earned $2.35 earnings per share. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.